Literature DB >> 7035980

Uremia and the liver. II. Drugs and the liver in the uremic patient.

P Simon, A Meyrier, P Brissot.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7035980     DOI: 10.1159/000182230

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


× No keyword cloud information.
  6 in total

1.  Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals.

Authors:  D A Sica; T J Comstock; J Davis; L Manning; R Powell; A Melikian; G Wright
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Clinical pharmacological studies with the vasodilator endralazine in patients with renal impairment.

Authors:  H L Elliott; P A Meredith; L Sloan; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Antipyrine metabolite formation and excretion in patients with chronic renal failure.

Authors:  M W Teunissen; D Kampf; I Roots; N P Vermeulen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.

Authors:  M S al-Ghamdi; F A al-Mohanna; Z H al-Mustafa; I S al-Saeed
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Pharmacokinetics of mepindolol in patients with chronic renal failure.

Authors:  W Krause; D Kampf; H C Fischer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of tenoxicam.

Authors:  O G Nilsen
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.